<code id='81ED794DDC'></code><style id='81ED794DDC'></style>
    • <acronym id='81ED794DDC'></acronym>
      <center id='81ED794DDC'><center id='81ED794DDC'><tfoot id='81ED794DDC'></tfoot></center><abbr id='81ED794DDC'><dir id='81ED794DDC'><tfoot id='81ED794DDC'></tfoot><noframes id='81ED794DDC'>

    • <optgroup id='81ED794DDC'><strike id='81ED794DDC'><sup id='81ED794DDC'></sup></strike><code id='81ED794DDC'></code></optgroup>
        1. <b id='81ED794DDC'><label id='81ED794DDC'><select id='81ED794DDC'><dt id='81ED794DDC'><span id='81ED794DDC'></span></dt></select></label></b><u id='81ED794DDC'></u>
          <i id='81ED794DDC'><strike id='81ED794DDC'><tt id='81ED794DDC'><pre id='81ED794DDC'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:688
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          BD to buy Edwards patient monitoring unit for $4.2 billion
          BD to buy Edwards patient monitoring unit for $4.2 billion

          IanWaldie/GettyImagesBectonDickinsonplanstopay$4.2billionforEdwardsLifesciences’criticalcarebusiness

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

          CourtesyBristolMyersSquibbBristolMyersSquibbsaidthatitwouldpurchaseMiratiTherapeutics,makerofthecanc